The beginning 2013-2014
First trials of inPROBE on animal cells
SDS Optic develops 6 micron diameter optical fibre tip: the base technology of improve
First presentations of the inprobe technology in the USA and Europe, receiving positive testimonials from KOLs
2015
The National Centre of Research and Development (NCBiR) grants €2,6M to cover all R&D expenses
2016
First in vitro testing results
Technology is validated and capable to measure different cancer biomarkers in real time
2017
SDS Optic applies for 2 independent patents in PCT worldwide procedure
Pre clinical - Pre-Clinical testing on mouse and rat models
SME - grants almost €4M funding to run clinical trials and implement commercialisation strategy
2018
R&D Centre kick off in Lublin. Team of Biology, Chemist, Physics & Engineering PhDs’ and MScs’
INNOventure VC fund invests €750K into R&D CapEx and reserch activities
2019
ContentFinal stage of Pre-Clinical trials on rat models with human HER2 overexpressing breast cancer cell lines delivered from living cancer Patients
SDS Optic Ltd. becomes SDS Optic Inc.
First technology scale up opportunities in vitro studies
Kicking off Clinical Trials with ethical committee & regulatory approvals granted
2020
Ongoing Clinical Trials for HER2+ Breast Cancer diagnostics application
Technology Scale Up
Pre-IPO Series A funding
Introducing new long term company strategy focusing on R&D, platform technology Scale Up and M&A of Lifesaving Innovations
2021
Clinical trials completion
CE Mark and ISO13485 Certification
IPO and long term enterprise value building for shareholders
Wide Core Technology Applications - new tumor cancer, endoscopy app, therapies monitoring, surgical oncology
2022
FDA & EMA Approvals for HER2+ Breast Cancer diagnostics application
Market Go Live
Long Term enterprise value delivery for shareholders
Global Organization with at least 2 R&D Centres overseas